SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing a massive surge in trading volume and investor interest as the community positions itself ahead of a critical May FDA decision for its ADHD drug, CTx-1301. Investors are actively discussing the potential impact of an anticipated U.S. patent approval on the stock, drawing parallels to previous market rallies while debating the impact of recent financing moves on the company's long-term valuation.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently under heavy scrutiny as investors weigh the impact of recent capital raises against anticipation for late-stage clinical trial results for its psilocybin-based treatment. While the community remains divided between those expressing frustration over share dilution and those holding for a potential long-term buyout or market-leading approval, technical traders are actively monitoring the stock's support levels as it consolidates near key psychological marks.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders closely monitor geopolitical instability in the Strait of Hormuz and rising oil prices, with the community actively debating whether current volatility metrics are being suppressed or if a major market correction is imminent. Investors remain divided, with many aggressively adding to positions as an insurance hedge against a potential global market pullback, while others caution against the structural decay inherent in leveraged volatility products.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is currently moving alongside fluctuations in natural gas futures as traders weigh the impact of seasonal shoulder season transitions against ongoing geopolitical risks in the Middle East. The community remains divided, with active discussions debating whether to play the potential for extreme volatility driven by supply chain disruptions or to bet on a return to fundamental bearish trends as warming weather forecasts emerge.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is capturing significant trader attention as the community debates its potential inclusion in upcoming payment initiatives, despite ongoing skepticism from bears regarding its long-term price action. While some investors see the current consolidation as a prime accumulation phase for a future breakout, others remain wary of repetitive dump patterns and frequent market volatility.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is seeing intense trading activity as market participants clash over conflicting narratives surrounding Middle East geopolitical disruptions and U.S. natural gas fundamentals. Community members are actively debating whether the ongoing supply-chain volatility in the Strait of Hormuz will trigger a sustained price breakout or if high storage levels and shoulder-season demand will ultimately lead to another technical collapse.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense community debate as investors weigh persistent price stagnation and frustration with leadership against the potential of its long-term ecosystem development and institutional integrations. While some participants are aggressively accumulating during current price levels, others are increasingly vocal about the lack of transparent progress and the asset's failure to decouple from broader market volatility.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

British drugmaker GSK Plc (GSK) on Wednesday announced that it now expects full-year earnings and turnover to be toward the top end of its guidance after its second-quarter earnings surpassed Wall Street expectations on strong sales of its specialty medicines.The company now <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf">expects</a> turnover growth to be toward the top end of 3% to 5% and for core earnings per share growth to be closer to 8% at constant exchange rate.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GSK">GSK</a> trended in the ‘bearish’ territory over the past 24 hours, while message volume dropped from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_8_18_14_AM_png_6f597ae2a0.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>CEO Emma Walmsley pegged the increase in guidance to another quarter of excellent performance, driven by the company’s specialty medicines segment.“We also continue to make very good progress in research and development, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year. With all this, we now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks," the CEO said.GSK is eyeing annual sales of over £40 billion ($53.28 billion) by 2031. &nbsp;The company on Wednesday noted that its guidance is inclusive of tariffs enacted by the U.S. thus far and European tariffs indicated this week.“We are positioned to respond to the potential financial impact of tariffs, with mitigation options identified. Given the uncertain external environment, we will continue to monitor developments,” the firm said.For the second quarter, the company reported sales of about £8.00 billion, marking a growth of 6% at constant exchange rate and above an analyst estimate of £7.81 billion, according to data from Fiscal AI.Specialty medicines sales rose 15% to £3.3 billion, thanks to double-digit sales growth in Respiratory, Immunology &amp; Inflammation, Oncology, and HIV drugs at constant exchange rate.Vaccine sales, meanwhile, rose 9% to £2.1 billion while general medicines sales fell 6%.Core earnings per share came in at 46.5 pence in the three months through the end of June, up from an analyst estimate of 42 pence.NYSE-listed shares of GSK are up by over 11% this year but down by over 5% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.33)

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

Equity

U.S. Food and Drug Administration reviewers on Tuesday flagged certain concerns about GSK Plc’s (GSK) investigational cancer drug called Blenrep, including a high rate of ocular toxicities.Ocular toxicity refers to the harmful effects a substance or drug has on the eye, potentially causing damage to its structure or impairing its function.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is seeking approval for the drug, also known as Belantamab Mafodotin, in the treatment of adults with multiple myeloma in combination with Bortezomib or Pomalidomide and Dexamethasone in patients who have received at least one prior line of therapy. The application is based on data from two late-stage trials.FDA reviewers <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/media/187578/download">stated</a> in briefing documents on the regulator’s website that the benefit-risk profile of the drug for treating multiple myeloma “remains unclear,” considering efficacy results, safety and tolerability concerns, and uncertainties regarding the appropriateness of the proposed dosages.The documents were released ahead of an advisory committee meeting scheduled for Thursday. The FDA is expected to decide on approving or disapproving the drug by next week.The reviewers noted a high incidence of ocular toxicity with the treatment, including keratopathy (changes in the corneal epithelium), changes in clarity of vision, as well as other ocular symptoms, such as blurred vision and dry eyes.“The ocular toxicity, including corneal toxicity, observed with Belantamab Mafodotin is a unique toxicity that is not seen with any currently available treatments for multiple myeloma,” they said.While ocular toxicity may be asymptomatic in its early stages, it can result in severe consequences, such as loss of vision, the reviewers noted.The agency also expressed concern that the dosages of Belantamab Mafodotin have not been adequately optimized, as evidenced by the high rates of dose modifications in both trials referred to in the application.A majority of patients were not receiving the intended dosage and required frequent dose modifications, including interruptions, throughout the duration of treatment, the agency said.Blenrep was previously granted accelerated approval as monotherapy on Aug. 5, 2020, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. It was subsequently withdrawn on Feb. 6, 2023, due to failure of the confirmatory trial to meet its progression-free survival endpoint.On Stocktwits, retail sentiment about GSK fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_15_at_1_26_26_PM_png_1594f6ef5c.webp" alt="GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits</figcaption></figure>GSK stock is up 6% this year but down by 4% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-stock-flies-on-expansion-of-marina-site/ch8Q95jR5Fw">Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.”

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the disease has been accepted by the U.S. Food and Drug Administration (FDA).The vaccine is currently approved in the U.S. for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. Adults can be at increased risk for RSV disease due to certain comorbidities, immune-compromised status, or advanced age.A regulatory decision by the FDA on this submission is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/">expected</a> in the first half of 2026.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is continuing to seek expanded indications for its RSV vaccine in other geographies, including in the European Economic Area and Japan, the company said.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, as per GSK. RSV can exacerbate conditions, including Chronic Obstructive Pulmonary Disease (COPD), asthma, and chronic heart failure, and can lead to severe outcomes, such as pneumonia, hospitalization, and death.Arexy’s turnover fell 57% in the first quarter (Q1) of 2025 to £78 million ($105 million) due to lower demand. The company pegged the decline in sales within the U.S. partly to a more limited recommendation from the Advisory Committee on Immunization Practices for individuals aged 60 to 74.On Stocktwits, retail sentiment around GSK stayed unmoved within ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_8_31_53_AM_png_fd0d117e35.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="130"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are up by 13% this year but down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-ansys-35-billion-deal-reportedly-gets-china-conditional-approval/ch8Bx5yR5V8">Synopsys-Ansys’ $35B Deal Reportedly Gets China’s Conditional Approval Days Before Closure Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.35)

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance

A decision by the FDA on the new submission is expected in the first half of 2026.

Fidelity Covington Trust - Fidelity Women's Leadership

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

FDWM
Fidelity Covington Trust - Fidelity Women`s Leadership ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FDWM News

FDWMFidelity Covington Trust - Fidelity Women`s Leadership ETF